M
MYND
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, MYND has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +133% compared to the S&P TSX Composite Index (Canada)'s +43% growth.
Stocks Performance
MYND vs S&P TSX Composite Index (Canada)
Performance Gap
MYND vs S&P TSX Composite Index (Canada)
Performance By Year
MYND vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
MYND Life Sciences Inc
Glance View
MYND Life Sciences, Inc. is a neuro-pharmaceutical drug development company. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2021-05-26. The firm is focused on conducting research linking depression and inflammation at the genetic and cellular level to develop a pharmaceutical treatment utilizing compounds found in psychedelics with the initial focus being on psilocybin and its various analogs. The company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials with an initial focus on Major Depressive Disorder (MDD). The Company’s lead development program, referred to as the Human Mycogene Modulation program (HMM), is designed to treat neuropsychiatric disorders through the dosing of formulations of psilocybin. The company is evaluating additional indications for its HMM program, including autoimmune disorders (AD) and other MDD conditions.
